Glaukos Corporation (NYSE: GKOS) announced results from a long-term Phase 3 extension study evaluating its Epioxa corneal cross-linking therapy for keratoconus, showing sustained efficacy and safety ...

Three-year data demonstrate sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable long-term safety profile following a single treatment. Glaukos ...

This live blog has now finished. Thank you for joining us throughout this Amazon sale. We hope you managed to find what you ...

Snap up these budget-friendly finds before they sell out ...

Amazon Prime Big Deal Days is here, and the Mic shopping editors rounded up the very best fashion and beauty finds.